Mevion installs first MEVION S250i with HYPERSCAN pencil beam scanning

LITTLETON, Mass., April 4, 2017 – Mevion Medical Systems announces the installation of the first MEVION S250i with HYPERSCAN, Mevion’s advanced proton therapy pencil beam scanning system, at MedStar Georgetown University Hospital. This breakthrough technology, will allow MedStar Georgetown to deliver a new standard of Intensity Modulated Proton Therapy (IMPT) combining the fastest energy modulation with the sharpest lateral penumbra improving the treatment options available to cancer patients. This is the first installation of HYPERSCAN with Adaptive Aperture, Mevion’s novel proton multi-leaf collimator. The installation at MedStar Georgetown will be followed by a MEVION S250i installation at Zuidoost Nederland Protonen Therapie Centrum, co-located at the Maastricht Clinic, in the Netherlands and at the Ackerman Cancer Center in Jacksonville, Florida, which will be the second unit installed at the private, physician run center.

“Mevion is proud to be working with MedStar Georgetown to achieve this milestone, and to be making proton therapy accessible to the Washington D.C. area. HYPERSCAN with Adaptive Aperture represents a real paradigm shift for the entire industry. This is the only proton system able to precisely shape each energy layer and deliver those layers at speeds up to 50 times faster than other systems. The results are highly conformal proton dose distributions that can be automatically adapted as treatment progresses.” said Joseph K. Jachinowski, president and CEO of Mevion Medical Systems.

The Adaptive Aperture is a proprietary low-profile micro-multi-leaf collimator system designed specifically for HYPERSCAN pencil beam scanning. It eliminates the need for manual apertures and adjustments because its unique layer-by-layer beam collimation achieves unprecedented one to three millimeter collimated effective spot sizes for all energies. HYPERSCAN with Adaptive Aperture is capable of scanning a typical lung tumor in less than two seconds – eliminating many of the challenges caused by patient motion that other pencil beam scanning systems encounter.

Proton therapy provides targeted radiation treatment for many types of cancer, significantly reducing the dose of radiation to healthy tissue by as much as a factor of three, while still maintaining high conformance to the treatment target. Mevion developed the world’s first compact proton therapy system to help increase access to this valuable therapy and currently has more compact systems under contract, installed and treating patients than any other proton therapy manufacturer.

About the MEVION S250 Series™

The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefitting from Mevion’s patented direct beam technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is a high-quality treatment with reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers. The MEVION S250 Series includes:

MEVION S250 Proton Therapy System®, offering highly stable, next-generation volumetric delivery capabilities

MEVION S250i Proton Therapy System™ with HYPERSCAN™ and Adaptive Aperture™, overcoming pencil beam scanning uncertainties by delivering robust IMPT treatment at hyper-speed

MEVION S250mx™, making proton therapy fully scalable, with two, three and four room designs that are inherently redundant and support 100% facility uptime

The MEVION S250i Proton Therapy System with HYPERSCAN and Adaptive Aperture has not been cleared by the USFDA for clinical use.

©

IBA adds two treatment rooms to South China Guangdong collaboration

LOUVAIN-LA-NEUVE, Belgium, 1 July 2015 – IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed an extension to the collaboration agreement with Guangdong Hengju Medical Technologies Co. Limited. This binding agreement for two additional gantry treatment rooms, equipped with the next generation Pencil Beam Scanning capability, is worth approximately €20m to IBA.

In December 2014, IBA signed its first collaboration agreement with Guangdong Hengju Medical Technologies Co. Limited to jointly install the first proton therapy system in South China. This agreement is worth approximately €30m to IBA. With a total of three rooms planned, the facility is expected to open in 2017.

Olivier Legrain, chief executive officer, IBA, commented: "This extension of our collaboration with Guangdong Hengju Medical Technologies Co. Limited confirms IBA's position as a trusted partner for the development and delivery of proton therapy treatment facilities around the world. We are delighted to have built upon our original contribution to this collaboration to jointly install the first proton therapy system in South China."

Mr Xiao Xue, chairman, Guangdong Hengjian Investment Holding Co Ltd, commented: "Guangdong Hengju Medical Technologies Co. Limited Proton Therapy facility enjoys full support from various Chinese governments, and is listed as a National Key Project. This second collaboration with IBA, the global leader in proton therapy, is very significant and is an important milestone for future long-term partnership between both companies."

Mr Wang Jian, executive director Guangdong Hengju Medical Technologies Co Ltd, added: "The signing of this second agreement will increase the rate of future developments and provide the chance to train our team and increase the level of medical expertise in Guangdong Province."

About Guangdong Heng Ju Medical Technologies Co Limited

Guangdong Hengjian Investment Holding Co. Ltd is the financing and investment platform of the Guangdong provincial government. Guangdong Hengju Medical Technologies Co Limited is the first company in China focusing on the development and expansion of proton therapy in China under the spirit of 'Government Supported, Corporatized Management and Market Oriented'.

©

Proton Partners International acquires site for UK's first proton therapy centre

CARDIFF, UK, 29 June 2015 - Proton Partners International Limited announced today it has completed the acquisition of the site where the first High Energy Proton Beam Therapy cancer treatment centre will be built in the UK.

The centre will be situated at Celtic Springs Business Park, Newport. Renovation of the site will begin next week and the centre is due to be operational next year.

Mike Moran, chief executive officer of Proton Partners International Ltd., said: "We are delighted to have completed the acquisition of the site and work will begin immediately. We are working very closely with the Welsh Government and the Wales Life Sciences Fund to create what will be a step change in cancer treatment in the UK."

The Newport centre is the first of three Proton Beam Therapy centres which will be built by Proton Partners International in the UK. The other sites will be in Northumberland and London with additional sites identified in Liverpool and Birmingham.

Proton Partners International Limited has appointed global partners to provide class-leading clinical equipment and innovative technology solutions for their UK centres. 

IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, has been selected to install its single-room proton therapy system, Proteus®ONE.

Philips has been appointed to deliver software and technology tools including Philips' Pinnacle Treatment Planning which delivers an intuitive planning environment that simplifies workflow. Philips will also provide big bore CT scanners at each centre and a PET CT in the Newport centre.

©

IBA to install three compact proton therapy centres in the UK

LOUVAIN-LA-NEUVE, BELGIUM, 25 June 2015 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed three separate binding term sheets, containing significant and immediate down-payments, with Proton Partners International (PPI), to install three of its Proteus®ONE compact proton therapy solutions in private clinics in the United Kingdom.

Each term sheet covers delivery of the Proteus®ONE equipment, including next generation Pencil Beam Scanning (PBS) and Cone Beam CT (CBCT) capabilities, and a ten-year maintenance agreement. The typical end-user price for a Proteus®ONE system with such a maintenance contract is between EUR 35 and 40 million. These three centers will be the eighth, ninth and tenth installations of IBA’s compact single-room proton therapy solution and are expected to treat the first patients in 2017.

The proton therapy center in Newport will treat patients from Wales, the south-west of England and the Midlands, and the center in Newcastle will treat patients from the North of England. The location of the third center will be announced at a later date.

These three projects follow the framework agreement that IBA and Philips signed in September 2014 to advance the diagnosis and treatment of cancer and demonstrate the efficiency of the collaboration between the two organizations.

Olivier Legrain, Chief Executive Officer of IBA, commented: “We are delighted that IBA has been selected by Proton Partners International to build its three proton therapy centers, bringing access to the most advanced radiation therapy technology to cancer patients across the United Kingdom. PPI’s choice of IBA not only strengthens our world leading position in proton therapy, but also demonstrates the preference of IBA as the most experienced proton therapy provider in the market and the fastest from signing to treatment.”

Mike Moran, Chief Executive Officer of Proton Partners International Limited, added: "We are delighted to announce that we will be working with IBA, the world leader in proton therapy technology, who will equip our centres to the highest specifications. We are excited about the opportunity to deliver the first high energy Proton Beam Therapy Centres in the UK and we look forward to working with a range of stakeholders to help support the research effort in the wider use of proton beam therapy for the benefit of the patients from all over UK."

©